Biosimilars and Interchangeable Biologics - Tactical Elements

Even very established companies have made mistakes when developing biosimilar products. For example, not appreciating future threats to intellectual property caused a biosimilar product development plan to fail after millions were spent. Additional pitfalls include not anticipating the next line of improved products, better formulations, deliver